- Home
- XERS vs LADR Comparison
XERS vs LADR Comparison
Compare XERS & LADR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | LADR |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | XERS | LADR |
|---|---|---|
| Price | $10.51 | $8.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $12.86 | $12.00 |
| AVG Volume (30 Days) | ★ 2.3M | 1.4M |
| Earning Date | 11-05-2026 | 10-22-2026 |
| Dividend Yield | N/A | ★ 10.39% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $32.91 | $13.72 |
| Revenue Next Year | $23.75 | $2.59 |
| P/E Ratio | ★ N/A | $63.21 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $5.25 | $8.48 |
| 52 Week High | $10.35 | $11.48 |
Technical Indicators
Market Signals| Indicator | XERS | LADR |
|---|---|---|
| Relative Strength Index (RSI) | 69.93 | 34.63 |
| Support Level | $7.15 | N/A |
| Resistance Level | N/A | $10.39 |
| Average True Range (ATR) | 0.52 | 0.18 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 99.03 | 27.33 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About LADR Ladder Capital Corp
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments: Loans, which derive maximum revenue; Securities; and Real Estate.